4Q Revenues: $126.4 million (+46%)
4Q Earnings: $1.8 million (loss of $1.9 million 4Q14)
FY Revenues: $402.3 million (+45%)
FY Loss: $2.3 million (loss of $3.3 million FY14)
Comments: Contract revenue for the quarter was $123.0 million, up 52%. Margins benefited from recent acquisitions, product mix within the Drug Product segment and the impact of cost reduction initiatives and facility optimization activities. Royalty revenue in the quarter was $3.4 million, down 43% due to lower royalties on Allegra products, which have ended based on the patent expirations.